

Case Report

Phenobarbital Treatment For Malignant Infarcts: A Case Report

Singh S*

*Samarth Singh, MBBS, MD, FINS, MBA

HOD, Department of Interventional Neurology, NeuroCardio & Multispeciality Hospital, Biratnagar, Nepal

Correspondence: drsamarthsingh@yahoo.com

Summary

Malignant infarct is a well established cause of morbid raised ICP. The mainstay of management remains osmotic diuresis and hyperosmolar therapy. Hyperventilation, hemicraniectomy and hypothermia also have good outcomes. Phenobarbitals are used in cases of refractory raised ICP. We present a case of malignant Rt. MCA infarction where phenobarbital, instead of well established agents like pentobarbital and thiopental was used. The aim was to prevent cytotoxic edema within 48 hrs of ictus. The desired effects of phenobarbital was noted on repeat CT scan with restricted perilesional edema, without any significant drop in GCS. Neurological examination was possible, which is not possible with pentobarbital and thiopental.

Keywords: malignant infarct, raised ICP, cerebral edema, barbiturate coma, phenobarbital

Introduction

Barbiturates, mainly pentobarbital is the drug of choice for treatment of refractory raised ICP, there are also reports of thiopental sodium being used to manage raised ICP. Raised ICP in ischemic infarcts occur due to malignant infarcts.¹ Any infarct > 50 % of MCA territory or > 145ml (Kothari's formula) can be predicted to behave malignantly.² Malignancy implies to the cytotoxic edema that surround the infarct area. This is disruption of Monroe Kelly doctrine, causes raised ICP and presents as raised ICP leading to herniation. Numerous agents like mannitol, hypertonic saline, hyperventilation, CSF diversion and hemicraniectomy have been used to treat raised ICP of malignant infarcts. Barbiturates are recommended at the end of protocols when raised ICP is deemed refractory. We present a case of malignant right MCA infarct which was managed with barbiturate; phenobarbital to prevent the edema which is maximum about 48 hrs from the onset of infarct.

Case Presentation

A 65 yr old diabetic male patient presented with sudden decrease in sensorium and preferential movement of right extremities. The GCS of the patient was E3V3M5 and the pupils were isocoric. A MRI DWI (Fig:1) was performed which revealed > 50 percent of right MCA infarction. The patient was admitted to the NCCU (NeuroCritical Care Unit). He maintained the blood gases and he was put on nasal O₂, not requiring intubation. A single dose of mannitol 150 cc, atorvastatin and other medicines were given. Aspirin was held for 2 days as it may aggravate HT (Hemorrhagic Transformation) which has a higher occurrence in the first 48 hrs. Along with the above medicines he was also given single dose of 400 mg of phenobarbital followed by 100 mg q8 hrs intravenously.

The sensorium of the patient decreased, GCS (E3V3M4) with marked hemiparesis of right side for the next day. However the vitals were stable. 48 & 90 hrs post ictus a CT scan (Fig:2) was done which showed a

Figure





Fig.1 : MRI -DWI ADC showing Rt MCA malignant infarct; 6 hrs post ictus





Fig.2 : CT Scan (A) 48 hrs after ictus, (B) 90 hrs after ictus

stable infract with minimal edema and stable midline shift, similar findings were noted on subsequent scans. Four days later the patient was shifted to ward with E4V4M6, right hemiparesis, and the NCCU stay was uneventful. After fifteen day the power of right hemiparesis was 4/5 and resolved completely after a month, with mRS0.

Discussion

There are numerous mechanisms of cerebral edema, cytotoxic edema is caused by cellular injury secondary to ischemia, as a result there is cellular edema which accounts to malignant effect on the cerebral compliance. As the volume of edema increases it causes raised ICP leading to undesired effects, most notoriously herniation.³ Pentobarbital and thiopental are well established agents used to treat raised ICP.^{4,5,6} High doses of barbiturates have been used in past with remarkable reductions in ICP, with favourable outcome.⁷ Notably both require intubation and ventilatory support. Phenobarbital is a well established antiepileptic prescribed in OPD (outpatient department) as an oral agent. The same can be used intravenously with out the warranted ventilatory support.

In this case phenobarbital was chosen as the patient was awake and ventilatory support was not indicated. A >50% of MCA infarct was a certain predictor of the malignant imminent, hence it was decided to start barbiturate to prevent edema and not to wait for it may become refractory. Low dose (400mg) of

phenobarbital was loaded, suboptimal by loading standards of seizures and a maintenance doses (100 mg qid) were administered (weight of patient 58 kg). Thus over sedation was avoided at the same time not requiring intubation as with the other two barbiturates. Pentobarbital limits neuroexamination allowing only celiacocolic reflex and thiopental also limits neuroexamination. However phenobarbital, provides a broader range of neuroexamination and all patients might not require ventilatory support. After 48 hrs we started tapering phenobarbital and it was stopped after 7 days.

Conclusion

This is an anecdotal case of prevention of cytotoxic cerebral edema following administration of a lesser barbiturate used for ICP reduction, however the effect and outcome is remarkable and well noted. We suggest more studies to validate phenobarbital for prevention of raised ICP in malignant edema rather than for management of refractory edema, with out ventilatory support and with a broader window for neuroexamination.

References

1. Bader MK, Arbour R, Palmer S. Refractory increased intracranial pressure in severe traumatic brain injury: barbiturate coma and bispectral index monitoring. *AACN Advanced Critical Care*. 2005 Oct 1;16(4):526-41
2. Treadwell SD, Thanvi B. Malignant middle cerebral artery (MCA) infarction: pathophysiology, diagnosis and management. *Postgraduate medical journal*. 2010 Apr 1;86(1014):235-42.
3. Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. *Journal of Cerebral Blood Flow & Metabolism*. 2016 Mar;36(3):513-38
4. Majdan M, Mauritz W, Wilbacher I, Brazinova A, Rusnak M, Leitgeb J. Barbiturates use and its effects in patients with severe traumatic brain injury in five European countries. *Journal of neurotrauma*. 2013 Jan 1;30(1):23-9.
5. Pérez-Bárcena J, Llompарт-Pou JA, Homar J, Abadal JM, Raurich JM, Frontera G, Brell M, Ibáñez J, Ibáñez J. Pentobarbital versus thiopental in the treatment of refractory intracranial hypertension in patients with traumatic brain injury: a randomized controlled trial. *Critical Care*. 2008 Aug;12(4):R112.
6. Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke Useful or obsolete?. *Neurology*. 1997 Jun 1;48(6):1608-13.
7. Woodcock JO, Ropper AH, Kennedy SK. High dose barbiturates in non-traumatic brain swelling: ICP reduction and effect on outcome. *Stroke*. 1982 Nov 1;13(6):785-7.